Point-of-Care Urine Lipoarabinomannan Testing to Guide Tuberculosis Treatment Among Severely Ill Inpatients With Human Immunodeficiency Virus in Real-World Practice: A Multicenter Stepped Wedge Cluster-Randomized Trial From Ghana
Open Access
- 26 May 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 77 (8) , 1185-1193
Abstract
The lateral flow urine lipoarabinomannan assay, Determine TB-LAM (Determine LAM), offers the potential for timely tuberculosis (TB) treatment among people living with HIV (PWH). In this cluster-randomized trial, Determine LAM was made available with staff training with performance feedback at three hospitals in Ghana. Newly admitted PWH with a positive WHO four-symptom screen for TB, severe illness, or advanced HIV were enrolled. The primary outcome was days from enrollment to TB treatment initiation. We also reported the proportion of patients with a TB diagnosis, initiating TB treatment, all-cause mortality, and Determine LAM uptake at 8 weeks. We enrolled 422 patients including 174 (41.2%) in the intervention group. The median CD4 count was 87 cells/mm3 (IQR 25-205) and 138 patients (32.7%) were on antiretroviral therapy. More patients were diagnosed with TB in the intervention group compared with the control group, 59 (34.1%; 95%CI27.1-41.7) vs 46 (18.7%; 95%CI14.0-24.1), p . Time to TB treatment remained constant at a median of 3 days (IQR 1-8), but patients were more likely to initiate TB treatment, aHR 2.19 (95%CI1.60-3.00) during the intervention. Of patients with a Determine LAM test available, 41 (25.3%) tested positive. Of those, 19 (46.3%) initiated TB treatment. Overall, 118 patients had died (28.2%; 95%CI24.0-33.0) at 8 weeks follow-up. The Determine LAM intervention in real-world practice increased TB diagnosis and the probability of TB treatment but did not reduce time to treatment initiation. Despite high uptake, only half of the LAM-positive patients initiated TB treatment.Keywords
Funding Information
- Læge Agnethe Løvgreens Legat
- Torben og Alice Frimodts Fond
- A.P. Møller Fonden
- University of Southern Denmark
- Odense University Hospital
- Strategic Research Council
This publication has 24 references indexed in Scilit:
- Tuberculosis and non‐tuberculous mycobacteria among HIV‐infected individuals in GhanaTropical Medicine & International Health, 2016
- Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trialThe Lancet, 2016
- TB as a cause of hospitalization and in‐hospital mortality among people living with HIV worldwide: a systematic review and meta‐analysisJournal of the International AIDS Society, 2016
- Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana–findings from the DETECT HIV-TB studyBMC Infectious Diseases, 2015
- Promoting professional behaviour change in healthcare: what interventions work, and why? A theory-led overview of systematic reviewsBMJ Open, 2015
- Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settingsAIDS, 2015
- The stepped wedge cluster randomised trial: rationale, design, analysis, and reportingBMJ, 2015
- Perspectives on Introduction and Implementation of New Point-of-Care Diagnostic TestsThe Journal of Infectious Diseases, 2012
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- A systematic review of delay in the diagnosis and treatment of tuberculosisBMC Public Health, 2008